## Massimo Gennarelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9188719/publications.pdf

Version: 2024-02-01

218 papers 10,803 citations

53 h-index 92 g-index

232 all docs 232 docs citations

times ranked

232

14093 citing authors

#	Article	IF	CITATIONS
1	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	27.8	929
2	A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia. PLoS Genetics, 2009, 5, e1000373.	3.5	383
3	Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline †Predictors†and Longitudinal †Targetsâ€. Neuropsychopharmacology, 2013, 38, 377-385.	5.4	372
4	Serum and plasma BDNF levels in major depression: A replication study and meta-analyses. World Journal of Biological Psychiatry, 2010, 11, 763-773.	2.6	363
5	Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8708-8713.	7.1	272
6	Glucocorticoid-Related Molecular Signaling Pathways Regulating Hippocampal Neurogenesis. Neuropsychopharmacology, 2013, 38, 872-883.	5.4	262
7	Mutation within <i>TARDBP </i> leads to Frontotemporal Dementia without motor neuron disease. Human Mutation, 2009, 30, E974-E983.	2.5	220
8	Prenatal Diagnosis of Myotonic Dystrophy Using Fetal DNA Obtained from Maternal Plasma. Clinical Chemistry, 2000, 46, 301-302.	3.2	201
9	Blood microRNA changes in depressed patients during antidepressant treatment. European Neuropsychopharmacology, 2013, 23, 602-611.	0.7	197
10	Biomarkers and Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analyses. Journal of the American Academy of Child and Adolescent Psychiatry, 2012, 51, 1003-1019.e20.	0.5	192
11	Survival Motor-Neuron Gene Transcript Analysis in Muscles from Spinal Muscular-Atrophy Patients. Biochemical and Biophysical Research Communications, 1995, 213, 342-348.	2.1	182
12	Myotonic dystrophy: evidence for a possible dominant-negative RNA mutation. Human Molecular Genetics, 1995, 4, 599-606.	2.9	179
13	Association between â^'G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Molecular Psychiatry, 2001, 6, 79-82.	7.9	172
14	Selective Phosphorylation of Nuclear CREB by Fluoxetine is Linked to Activation of CaM Kinase IV and MAP Kinase Cascades. Neuropsychopharmacology, 2004, 29, 1831-1840.	5.4	171
15	Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. European Neuropsychopharmacology, 2006, 16, 620-624.	0.7	149
16	Peripheral whole blood microRNA alterations in major depression and bipolar disorder. Journal of Affective Disorders, 2016, 200, 250-258.	4.1	138
17	Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. Journal of Affective Disorders, 2006, 91, 83-86.	4.1	137
18	Serum Brain-Derived Neurotrophic Factor Levels in Different Neurological Diseases. BioMed Research International, 2013, 2013, 1-7.	1.9	137

#	Article	IF	CITATIONS
19	Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiology of Aging, 2014, 35, 934.e7-934.e10.	3.1	134
20	Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disorders, 2002, 4, 166-182.	1.9	110
21	Chronic Duloxetine Treatment Induces Specific Changes in the Expression of BDNF Transcripts and in the Subcellular Localization of the Neurotrophin Protein. Neuropsychopharmacology, 2007, 32, 2351-2359.	5.4	110
22	Reduced function of the serotonin transporter is associated with decreased expression of BDNF in rodents as well as in humans. Neurobiology of Disease, 2010, 37, 747-755.	4.4	107
23	Acute Stress Responsiveness of the Neurotrophin BDNF in the Rat Hippocampus is Modulated by Chronic Treatment with the Antidepressant Duloxetine. Neuropsychopharmacology, 2009, 34, 1523-1532.	5.4	104
24	Micro spies from the brain to the periphery: new clues from studies on microRNAs in neuropsychiatric disorders. Frontiers in Cellular Neuroscience, 2014, 8, 75.	3.7	100
25	Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biological Psychiatry, 2004, 55, 1095-1102.	1.3	99
26	Modulation of fibroblast growth factor-2 by stress and corticosteroids: from developmental events to adult brain plasticity. Brain Research Reviews, 2001, 37, 249-258.	9.0	92
27	Regulation of Editing and Expression of Glutamate α-Amino-Propionic-Acid (AMPA)/Kainate Receptors by Antidepressant Drugs. Biological Psychiatry, 2006, 59, 713-720.	1.3	92
28	Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics Journal, 2012, 12, 68-77.	2.0	92
29	Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. International Journal of Neuropsychopharmacology, 2010, 13, 103.	2.1	82
30	New Copy Number Variations in Schizophrenia. PLoS ONE, 2010, 5, e13422.	2.5	82
31	Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biological Psychiatry, 2002, 51, 480-484.	1.3	81
32	Exome Sequencing Followed by Large-Scale Genotyping Suggests a Limited Role for Moderately Rare Risk Factors of Strong Effect in Schizophrenia. American Journal of Human Genetics, 2012, 91, 303-312.	6.2	81
33	Markers of Alzheimer's disease in a population attending a memory clinic. Alzheimer's and Dementia, 2009, 5, 307-317.	0.8	80
34	Human Y-chromosome variation in the Western Mediterranean area: implications for the peopling of the region. Human Immunology, 2001, 62, 871-884.	2.4	79
35	5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neuroscience Letters, 2008, 437, 130-134.	2.1	79
36	Repetitive transcranial magnetic stimulation (rTMS) at high and low frequency: an efficacious therapy for major drug-resistant depression?. Clinical Neurophysiology, 2005, 116, 1062-1071.	1.5	78

#	Article	IF	CITATIONS
37	Serum levels of brain-derived neurotrophic factor in drug-naÃ⁻ve obsessive–compulsive patients: A case–control study. Journal of Affective Disorders, 2010, 122, 174-178.	4.1	76
38	miR-146a and miR-181a are involved in the progression of mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2019, 82, 102-109.	3.1	76
39	Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1322-1325.	4.8	73
40	Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity. Journal of Neuroscience Research, 2003, 72, 622-628.	2.9	68
41	The Expression of VGF is Reduced in Leukocytes of Depressed Patients and it is Restored by Effective Antidepressant Treatment. Neuropsychopharmacology, 2010, 35, 1423-1428.	5.4	68
42	Cognitive impairment and (CTG)n expansion in myotonic dystrophy patients. Biological Psychiatry, 1999, 46, 425-431.	1.3	67
43	Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801. NeuroReport, 2004, 15, 2109-2112.	1.2	66
44	Altered Gene Expression in Schizophrenia: Findings from Transcriptional Signatures in Fibroblasts and Blood. PLoS ONE, 2015, 10, e0116686.	2.5	65
45	Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. Neurogenetics, 2008, 9, 197-205.	1.4	63
46	VEGF serum levels in depressed patients during SSRI antidepressant treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 146-149.	4.8	61
47	Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochemistry International, 2011, 59, 896-905.	3.8	61
48	Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: Comparison with methylphenidate. Pharmacological Research, 2010, 62, 523-529.	7.1	60
49	Methylenetetrahydrofolate reductase and angiotensin converting enzyme gene polymorphisms in two genetically and diagnostically distinct cohort of Alzheimer patients. Neurobiology of Aging, 2003, 24, 933-939.	3.1	58
50	Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence. Cytokine, 2005, 30, 293-302.	3.2	58
51	The 196G/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder. Neuroscience Letters, 2006, 406, 133-137.	2.1	58
52	Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biological Psychiatry, 2003, 53, 617-619.	1.3	57
53	Long-Term Duloxetine Treatment Normalizes Altered Brain-Derived Neurotrophic Factor Expression in Serotonin Transporter Knockout Rats through the Modulation of Specific Neurotrophin Isoforms. Molecular Pharmacology, 2010, 77, 846-853.	2.3	56
54	BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 323-329.	3.2	54

#	Article	IF	Citations
55	Early raise of BDNF in hippocampus suggests induction of posttranscriptional mechanisms by antidepressants. BMC Neuroscience, 2009, 10, 48.	1.9	53
56	Association between IL- $1\hat{l}^2$ -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. Journal of Psychiatric Research, 2003, 37, 457-462.	3.1	52
57	Atypical dementia associated with a novel presenilinâ€2 mutation. Annals of Neurology, 2003, 54, 832-836.	5.3	51
58	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimer's and Dementia, 2013, 9, 677-686.	0.8	51
59	Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biological Psychiatry, 2001, 50, 117-122.	1.3	50
60	Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. Neuroscience Letters, 2004, 356, 119-122.	2.1	49
61	Stimulatory role of dopamine on fibroblast growth factorâ€2 expression in rat striatum. Journal of Neurochemistry, 2001, 76, 990-997.	3.9	48
62	Epidemiology of myotonic dystrophy in Italy: re-apprisal after genetic diagnosis. Clinical Genetics, 2002, 59, 344-349.	2.0	48
63	(CTG)n Triplet Mutation and Phenotype Manifestations in Myotonic Dystrophy Patients. Biochemical Medicine and Metabolic Biology, 1993, 50, 85-92.	0.7	47
64	A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial. Trials, 2012, 13, 73.	1.6	47
65	Seizure Adequacy Markers and the Prediction of Electroconvulsive Therapy Response. Journal of ECT, 2016, 32, 88-92.	0.6	47
66	Risk Prediction for Clinical Phenotype in Myotonic Dystrophy Type 1: Data from 2,650 Patients. Genetic Testing and Molecular Biomarkers, 2007, $11$ , 84-90.	1.7	46
67	-G308A tumor necrosis factor alpha functional polymorphism and schizophrenia risk: Meta-analysis plus association study. Brain, Behavior, and Immunity, 2007, 21, 450-457.	4.1	44
68	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology, 2010, 257, 2004-2014.	3.6	44
69	Variation in GNB3 predicts response and adverse reactions to antidepressants. Journal of Psychopharmacology, 2011, 25, 867-874.	4.0	44
70	Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiology of Aging, 2005, 26, 455-464.	3.1	43
71	ROLE OF ALLELIC VARIANTS OF FK506-BINDING PROTEIN 51 (FKBP5) GENE IN THE DEVELOPMENT OF ANXIETY DISORDERS. Depression and Anxiety, 2013, 30, 1170-1176.	4.1	42
72	Serum brain-derived neurotrophic factor (BDNF) levels in attention deficit–hyperactivity disorder (ADHD). European Child and Adolescent Psychiatry, 2014, 23, 173-177.	4.7	40

#	Article	IF	Citations
73	Non-Ceruloplasmin Copper Distincts Subtypes in Alzheimer's Disease: a Genetic Study of ATP7B Frequency. Molecular Neurobiology, 2017, 54, 671-681.	4.0	40
74	α-Synuclein and Glia in Parkinson's Disease: A Beneficial or a Detrimental Duet for the Endo-Lysosomal System?. Cellular and Molecular Neurobiology, 2019, 39, 161-168.	3.3	40
75	MCP-1 gene (SCYA2) and schizophrenia: A case-control association study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 132B, 1-4.	1.7	39
76	Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration. Neurobiology of Aging, 2011, 32, 555.e1-555.e8.	3.1	39
77	The influence of psychiatric screening in healthy populations selection: a new study and meta-analysis of functional 5-HTTLPR and rs25531 polymorphisms and anxiety-related personality traits. BMC Psychiatry, 2011, 11, 50.	2.6	39
78	Myotonic dystrophy: tissue-specific effect of somatic CTG expansions on allele-specific DMAHP/SIX5 expression. Human Molecular Genetics, 1999, 8, 1017-1023.	2.9	38
79	Serotonin transporter gene polymorphisms and treatment-resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 934-939.	4.8	38
80	Antidepressant Treatments Change 5-HT2C Receptor mRNA Expression in Rat Prefrontal/Frontal Cortex and Hippocampus. Neuropsychobiology, 2011, 63, 160-168.	1.9	38
81	Male Hypogonadism in Myotonic Dystrophy is Related to (Ctg)N Triplet Mutation. Journal of Endocrinological Investigation, 1994, 17, 381-383.	3.3	37
82	Antidepressants activate CaMKII in neuron cell body by Thr286 phosphorylation. NeuroReport, 2004, 15, 2393-2396.	1.2	37
83	The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis. Pharmacogenomics Journal, 2017, 17, 146-154.	2.0	37
84	Selective regulation of presynaptic Calcium/Calmodulin-Dependent protein kinase II by psychotropic drugs. Biological Psychiatry, 2003, 53, 442-449.	1.3	36
85	Alterations of Brain-Derived Neurotrophic Factor Serum Levels in Patients with Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2011, 35, no-no.	2.4	36
86	Expression of receptors for native and chemically modified low-density lipoproteins in brain microvessels. FEBS Letters, 1997, 401, 53-58.	2.8	35
87	The MCP-1 Gene (SCYA2) and Mood Disorders: Preliminary Results of a Case-Control Association Study. NeuroImmunoModulation, 2010, 17, 126-131.	1.8	35
88	Insulin-like Growth Factor 1 Differentially Affects Lithium Sensitivity of Lymphoblastoid Cell Lines from Lithium Responder and Non-responder Bipolar Disorder Patients. Journal of Molecular Neuroscience, 2015, 56, 681-687.	2.3	35
89	Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates. Frontiers in Pharmacology, 2019, 10, 402.	3.5	35
90	Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. Acta Psychiatrica Scandinavica, 2014, 129, 461-466.	4.5	34

#	Article	IF	CITATIONS
91	Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum. BioTechniques, 2014, 57, 111-114.	1.8	34
92	Glucose metabolism alterations in patients with bipolar disorder. Journal of Affective Disorders, 2015, 184, 293-298.	4.1	34
93	Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. European Journal of Human Genetics, 2006, 14, 443-449.	2.8	33
94	Extracellular clusterin limits the uptake of αâ€synuclein fibrils by murine and human astrocytes. Glia, 2021, 69, 681-696.	4.9	32
95	Expression Study of Survival Motor Neuron Gene in Human Fetal Tissues. Biochemical and Molecular Medicine, 1997, 61, 102-106.	1.4	31
96	Dementia, delusions and seizures: storage disease or genetic AD?. European Journal of Neurology, 2007, 14, 1057-1059.	3.3	31
97	Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 745-753.	1.7	31
98	Immune and metabolic alterations in first episode psychosis (FEP) patients. Brain, Behavior, and Immunity, 2018, 70, 315-324.	4.1	31
99	Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plasticity, 2018, 2018, 1-15.	2.2	31
100	No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. Journal of Alzheimer's Disease, 2006, 10, 371-378.	2.6	30
101	Role of Dopamine D2/D3 Receptors in Development, Plasticity, and Neuroprotection in Human iPSC-Derived Midbrain Dopaminergic Neurons. Molecular Neurobiology, 2018, 55, 1054-1067.	4.0	30
102	Association Study of –1727 A/T, –50 C/T and (CAA) <sub>n</sub> Repeat GSK-3β Gene Polymorphisms with Schizophrenia. Neuropsychobiology, 2004, 50, 16-20.	1.9	29
103	Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-9.	2.0	29
104	Next Generation Sequencing Analysis in Early Onset Dementia Patients. Journal of Alzheimer's Disease, 2019, 67, 243-256.	2.6	29
105	Clinical and hormonal aspects of male hypogonadism in myotonic dystrophy. Italian Journal of Neurological Sciences, 1996, 17, 59-65.	0.1	28
106	Serine/threonine kinases as molecular targets of antidepressants: implications for pharmacological treatment and pathophysiology of affective disorders., 2001, 89, 149-170.		28
107	The Emerging Role of SGK1 (Serum- and Glucocorticoid-Regulated Kinase 1) in Major Depressive Disorder: Hypothesis and Mechanisms. Frontiers in Genetics, 2020, 11, 826.	2.3	28
108	A Single Polymerase Chain Reaction-Based Protocol for Detecting Normal and Expanded Alleles in Myotonic Dystrophy. Diagnostic Molecular Pathology, 1998, 7, 135-137.	2.1	27

#	Article	IF	Citations
109	Allelic Variation in the Human Prodynorphin Gene Promoter and Schizophrenia. Neuropsychobiology, 2002, 46, 17-21.	1.9	27
110	Acute Footshock Stress Induces Time-Dependent Modifications of AMPA/NMDA Protein Expression and AMPA Phosphorylation. Neural Plasticity, 2016, 2016, 1-10.	2.2	27
111	Dopaminergic D2 receptor activation modulates FGFâ€2 gene expression in rat prefrontal cortex and hippocampus. Journal of Neuroscience Research, 2003, 74, 74-80.	2.9	26
112	Schizophrenia susceptibility and NMDA-receptor mediated signalling: an association study involving 32 tagSNPs of DAO, DAOA, PPP3CC, and DTNBP1genes. BMC Medical Genetics, 2013, 14, 33.	2.1	26
113	Proteasome system dysregulation and treatment resistance mechanisms in major depressive disorder. Translational Psychiatry, 2015, 5, e687-e687.	4.8	26
114	Copy number variants in attention-deficit hyperactive disorder. Psychiatric Genetics, 2015, 25, 59-70.	1.1	25
115	$3\hat{a}$ €2 UTR (AGG)n repeat of glial cell line-derived neurotrophic factor (GDNF) gene polymorphism in schizophrenia. Neuroscience Letters, 2004, 357, 235-237.	2.1	24
116	Genetic Variation in the G720/G30 Gene Locus (DAOA) Influences the Occurrence of Psychotic Symptoms in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 18, 953-960.	2.6	24
117	Human Elongation Factor EF- $1\hat{1}^2$ : Cloning and Characterization of the EF1 $\hat{1}^2$ 5a Gene and Assignment of EF- $1\hat{1}^2$ Isoforms to Chromosomes 2, 5, 15, and X. Biochemical and Biophysical Research Communications, 1993, 197, 154-162.	2.1	23
118	Clinical and medial temporal features in a family with mood disorders. Neuroscience Letters, 2010, 468, 93-97.	2.1	23
119	Biological correlates of early life stressful events in major depressive disorder. Psychoneuroendocrinology, 2021, 125, 105103.	2.7	23
120	International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic). European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 921-932.	3.2	22
121	Discordant clinical outcome in myotonic dystrophy relatives showing (CTG)n > 700 repeats. Neuromuscular Disorders, 1995, 5, 157-159.	0.6	21
122	Possible Influence of a Non-Synonymous Polymorphism Located in the NGF Precursor on Susceptibility to Late-Onset Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2012, 29, 699-705.	2.6	20
123	Atypical presentation of a novel Presenilin 1 R377W mutation: sporadic, late-onset Alzheimer disease with epilepsy and frontotemporal atrophy. Neurological Sciences, 2012, 33, 375-378.	1.9	20
124	PCLO gene: Its role in vulnerability to major depressive disorder. Journal of Affective Disorders, 2012, 139, 250-255.	4.1	20
125	Correlation of Sfil macrorestriction endonuclease fingerprint analysis of Candida parapsilosis isolates with source of isolation. Journal of Medical Microbiology, 1996, 45, 173-178.	1.8	19
126	Molecular signature of disease onset in Granulin mutation carriers: a gene expression analysis study. Neurobiology of Aging, 2013, 34, 1837-1845.	3.1	19

#	Article	IF	Citations
127	The role of <i>GRIK4</i> gene in treatment-resistant depression. Genetical Research, 2015, 97, e14.	0.9	19
128	BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients. Journal of ECT, 2019, 35, 189-194.	0.6	19
129	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. European Neuropsychopharmacology, 2022, 55, 86-95.	0.7	19
130	Two pedigrees of autosomal dominant atrioventricular canal defect (AVCD): Exclusion from the critical region on 8p. American Journal of Medical Genetics Part A, 1995, 57, 483-488.	2.4	18
131	Reduction of the DM-associated homeo domain protein (DMAHP) mRNA in different brain areas of myotonic dystrophy patients. Neuromuscular Disorders, 1999, 9, 215-219.	0.6	18
132	Genetic Counseling and Testing for Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Italian Consensus Protocol. Journal of Alzheimer's Disease, 2016, 51, 277-291.	2.6	18
133	Analysis of apoB, HLADQ alpha, and D1S80 polymorphisms in the Italian population using the polymerase chain reaction. American Journal of Human Biology, 1992, 4, 381-386.	1.6	17
134	Genetic Background Predicts Poor Prognosis in Frontotemporal Lobar Degeneration. Neurodegenerative Diseases, 2011, 8, 289-295.	1.4	17
135	MTHFR: Genetic variants, expression analysis and COMT interaction in major depressive disorder. Journal of Affective Disorders, 2015, 183, 179-186.	4.1	17
136	A novel homozygous mutation in GAD1 gene described in a schizophrenic patient impairs activity and dimerization of GAD67 enzyme. Scientific Reports, 2018, 8, 15470.	3.3	17
137	Blues in the Brain and Beyond: Molecular Bases of Major Depressive Disorder and Relative Pharmacological and Non-Pharmacological Treatments. Genes, 2020, 11, 1089.	2.4	17
138	miR-146a Plasma Levels Are Not Altered in Alzheimer's Disease but Correlate With Age and Illness Severity. Frontiers in Aging Neuroscience, 2020, 11, 366.	3.4	17
139	Combined $\hat{i}\pm 2$ -adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle. Psychopharmacology, 2001, 159, 105-110.	3.1	16
140	An Association of GRIK3 Ser310Ala Functional Polymorphism with Personality Traits. Neuropsychobiology, 2009, 59, 28-33.	1.9	16
141	BDNF Val66Met polymorphism and protein levels in Amniotic Fluid. BMC Neuroscience, 2010, 11, 16.	1.9	16
142	ErbB3 mRNA leukocyte levels as a biomarker for major depressive disorder. BMC Psychiatry, 2012, 12, 145.	2.6	16
143	The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia. Current Neuropharmacology, 2016, 14, 540-550.	2.9	16
144	Inflammation-related microRNAs are involved in stressful life events exposure and in trauma-focused psychotherapy in treatment-resistant depressed patients. Högre Utbildning, 2021, 12, 1987655.	3.0	16

#	Article	IF	Citations
145	Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients. Journal of Affective Disorders, 2017, 208, 443-447.	4.1	15
146	Childhood trauma and glucose metabolism in patients with first-episode psychosis. Psychoneuroendocrinology, 2020, 113, 104536.	2.7	15
147	Correlations between immune and metabolic serum markers and schizophrenia/bipolar disorder polygenic risk score in firstâ€episode psychosis. Microbial Biotechnology, 2020, 14, 507-511.	1.7	15
148	Behavioral and Psychological Symptoms of Dementia (BPSD): Clinical Characterization and Genetic Correlates in an Italian Alzheimer's Disease Cohort. Journal of Personalized Medicine, 2020, 10, 90.	2.5	15
149	Association study between <scp><i>HTR2A</i></scp> rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. Drug Development Research, 2020, 81, 754-761.	2.9	15
150	Exclusion of linkage with chromosome 21 in families with recurrence of non-Down's atrioventricular canal. Human Genetics, 1994, 94, 708-10.	3.8	14
151	Reduced activation of intracellular signaling pathways in rat prefrontal cortex after chronic phencyclidine administration. Pharmacological Research, 2008, 57, 296-302.	7.1	14
152	The effect of childhood trauma on blood transcriptome expression in major depressive disorder. Journal of Psychiatric Research, 2018, 104, 50-54.	3.1	14
153	Genetic determinants of circulating VEGF levels in major depressive disorder and electroconvulsive therapy response. Drug Development Research, 2020, 81, 593-599.	2.9	14
154	Exome sequencing in schizophrenic patients with high levels of homozygosity identifies novel and extremely rare mutations in the GABA/glutamatergic pathways. PLoS ONE, 2017, 12, e0182778.	2.5	14
155	Postzygotic instability of the myotonic dystrophy p[AGC]n repeat supported by larger expansions in muscle and reduced amplifications in sperm. Journal of Neurology, 1995, 242, 379-383.	3.6	13
156	First-trimester prenatal diagnosis of spinal muscular atrophy using microsatellite markers. Prenatal Diagnosis, 1994, 14, 459-462.	2.3	12
157	No association between Ala9Val functional polymorphism of MnSOD gene and schizophrenia in a representative Italian sample. Neuroscience Letters, 2006, 410, 208-211.	2.1	12
158	Serum leptin levels are higher in females affected by frontotemporal lobar degeneration than Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 79, 712-715.	1.9	12
159	Association study and mutational screening of SYNGR1 as a candidate susceptibility gene for schizophrenia. Psychiatric Genetics, 2009, 19, 237-243.	1.1	12
160	VEGF Haplotypes are Associated with Increased Risk to Progressive Supranuclear Palsy and Corticobasal Syndrome. Journal of Alzheimer's Disease, 2010, 21, 87-94.	2.6	12
161	Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues. World Journal of Biological Psychiatry, 2018, 19, 610-618.	2.6	12
162	Long-term treatment with s-adenosylmethionine induces changes in presynaptic cam kinase II and synapsin I. Biological Psychiatry, 2001, 50, 337-344.	1.3	11

#	Article	IF	CITATIONS
163	Decreased hippocampal BDNF expression after acute systemic injection of quinpirole. Neuropharmacology, 2001, 40, 954-957.	4.1	11
164	Study of the in vitro modulation exerted by the antidepressant drug escitalopram on the expression of candidate microRNAs and their target genes. Molecular and Cellular Neurosciences, 2017, 85, 220-225.	2.2	11
165	Classification of Psychoses Based on Immunological Features: A Machine Learning Study in a Large Cohort of First-Episode and Chronic Patients. Schizophrenia Bulletin, 2021, 47, 1141-1155.	4.3	11
166	Molecular Biomarkers of Electroconvulsive Therapy Effects and Clinical Response: Understanding the Present to Shape the Future. Brain Sciences, 2021, 11, 1120.	2.3	11
167	3? creatine kinase (M-type) polymorphisms linked to myotonic dystrophy in Italian and Spanish populations. Human Genetics, 1991, 87, 654-6.	3.8	10
168	Long-term soluble Aβ1–40 activates CaM kinase II in organotypic hippocampal cultures. Neurobiology of Aging, 2007, 28, 1388-1395.	3.1	10
169	The role of the potassium channel gene KCNK2 in major depressive disorder. Psychiatry Research, 2015, 225, 489-492.	3.3	10
170	Influence of GRIK4 genetic variants on the electroconvulsive therapy response. Neuroscience Letters, 2016, 626, 94-98.	2.1	10
171	Different Expression of the Myotonin Protein Kinase Gene in Discrete Areas of Human Brain. Biochemical and Biophysical Research Communications, 1995, 216, 489-494.	2.1	9
172	Lack of association between MnSOD gene polymorphism and sporadic Alzheimer's Disease. Aging Clinical and Experimental Research, 2005, 17, 445-448.	2.9	9
173	Understanding phenotype variability in frontotemporal lobar degeneration due to granulin mutation. Neurobiology of Aging, 2014, 35, 1206-1211.	3.1	9
174	Expansion of the myotonic dystrophy gene in Italian and Spanish patients Journal of Medical Genetics, 1992, 29, 789-790.	3.2	8
175	Effect of the Xbal polymorphism of estrogen receptor alpha on postmenopausal gray matter. Neuroscience Letters, 2008, 434, 304-309.	2.1	8
176	Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study. Neuropsychobiology, 2016, 74, 15-21.	1.9	8
177	Genome-wide analysis of consistently RNA edited sites in human blood reveals interactions with mRNA processing genes and suggests correlations with cell types and biological variables. BMC Genomics, 2018, 19, 963.	2.8	8
178	A tool for the molecular analysis of an early lethal disease: slide-PCR in spinal muscular atrophy patients. Molecular and Cellular Probes, 1993, 7, 221-226.	2.1	7
179	Identification of Multiple Transcribed Sequences from the Spinal Muscular Atrophy Region on Human Chromosome 5. Biochemical and Biophysical Research Communications, 1995, 206, 294-301.	2.1	7
180	Expression and phosphorylation of Î-CaM kinase II in cultured Alzheimer fibroblasts. Neurobiology of Aging, 2004, 25, 1187-1196.	3.1	7

#	Article	IF	Citations
181	Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2307-2312.	2.2	7
182	Genetic counselling and testing for inherited dementia: single-centre evaluation of the consensus Italian DIAfN protocol. Alzheimer's Research and Therapy, 2020, 12, 152.	6.2	7
183	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. European Neuropsychopharmacology, 2022, 55, 112-157.	0.7	7
184	Inosine-containing primers in human papillomavirus detection by polymerase chain reaction. Biomedicine and Pharmacotherapy, 1992, 46, 167-169.	5.6	6
185	North Eurasian origin of the myotonic dystrophy mutation. Human Mutation, 1994, 4, 79-81.	2.5	6
186	Further evidence on the lack of association between glycogen synthase kinase $3\hat{l}^2$ gene polymorphisms and bipolar disorder. Psychiatric Genetics, 2007, 17, 249-250.	1.1	6
187	Evidence of an interaction between <i>FXR1</i> and <i>GSK3<math>\hat{i}^2</math></i> polymorphisms on levels of Negative Symptoms of Schizophrenia and their response to antipsychotics. European Psychiatry, 2021, 64, e39.	0.2	6
188	Leucine-rich repeat kinase 2-related functions in GLIA: an update of the last years. Biochemical Society Transactions, 2021, 49, 1375-1384.	3.4	6
189	Cannabis and Psychosis: A Systematic Review of Genetic Studies. Current Psychiatry Reviews, 2013, 9, 302-315.	0.9	6
190	Study of the effects on DNA of electromagnetic fields using clamped homogeneous electric field gel electrophoresis. Biomedicine and Pharmacotherapy, 1991, 45, 451-454.	5.6	5
191	Assignment of the slow troponin T (TNNT1) gene to chromosome 19 using polymerase chain reaction. Human Genetics, 1992, 88, 697-698.	3.8	5
192	Focus The dynamic genomics of myotonic dystrophy and its clinical relevance: an overview. Biomedicine and Pharmacotherapy, 1993, 47, 321-330.	5.6	5
193	Assignment of the hexokinase type 3 gene (HK3) to human chromosome band 5q35.3 by somatic cell hybrids and in situ hybridization. Cytogenetic and Genome Research, 1996, 74, 187-188.	1.1	5
194	A putative regulatory subunit (NR3A) of the NMDA receptor complex as candidate gene for susceptibility to schizophrenia: a case–control study. Psychiatric Genetics, 2007, 17, 355-356.	1.1	5
195	Polymorphic CA repeat in IGF-I gene: lack of association with schizophrenia. Psychiatric Genetics, 2010, 20, 44-45.	1.1	4
196	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. World Journal of Biological Psychiatry, 2022, 23, 46-54.	2.6	4
197	Whole Blood Transcriptome Characterization of 3xTg-AD Mouse and Its Modulation by Transcranial Direct Current Stimulation (tDCS). International Journal of Molecular Sciences, 2021, 22, 7629.	4.1	4
198	Genomic instability associated with myotonic dystrophy does not involve p53 expression and activity. , 1998, $16, 117-122$ .		3

#	Article	IF	CITATIONS
199	Investigating the Role of Leukocyte Telomere Length in Treatment-Resistant Depression and in Response to Electroconvulsive Therapy. Journal of Personalized Medicine, 2021, 11, 1100.	2.5	3
200	Genotyping of spinal muscular atrophy families with linked DNA probes. Clinical Genetics, 1992, 42, 317-319.	2.0	2
201	Assessment of haptoglobin alleles in autism spectrum disorders. Scientific Reports, 2020, 10, 7758.	3.3	2
202	Establishment and characterization of induced pluripotent stem cell (iPSCs) line UNIBSi014-A from a healthy female donor. Stem Cell Research, 2021, 51, 102216.	0.7	2
203	Intermediate lengths of the C9ORF72 hexanucleotide repeat expansion may synergistically contribute to attention deficit hyperactivity disorder in child and his father: case report. Neurocase, 2021, 27, 138-146.	0.6	2
204	Genetic Dissection of Temperament Personality Traits in Italian Isolates. Genes, 2022, 13, 4.	2.4	2
205	Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA) Tj ETQq $1\ 1\ 0.7$	78 <b>4</b> 34 rg	BT‡Overlock
206	Compound heterozygosity for a hemizygous rare missense variant (rs141999351) and a large CNV deletion affecting the FSTL5 gene in a patient with schizophrenia. Psychiatry Research, 2017, 258, 598-599.	3.3	1
207	Investigating an in silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression. Pharmacogenomics Journal, 2021, 21, 85-93.	2.0	1
208	Alterations observed in the interferon $\hat{l}_{\pm}$ and $\hat{l}^{2}$ signaling pathway in MDD patients are marginally influenced by cis-acting alleles. Scientific Reports, 2021, 11, 727.	3.3	1
209	Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19. Pharmacological Research, 2021, 164, 105402.	7.1	1
210	Generation of two human induced pluripotent stem cell lines, UNIBSi012-A and UNIBSi013-A, from two patients with treatment-resistant depression. Stem Cell Research, 2020, 49, 102104.	0.7	1
211	Genome-wide association studies on Northern Italy isolated populations provide further support concerning genetic susceptibility for major depressive disorder. World Journal of Biological Psychiatry, 2023, 24, 135-148.	2.6	1
212	High conservation of the trinucleotide [CTG]n repeat at the myotonic dystrophy locus in nonhuman primates. Human Evolution, 1994, 9, 315-321.	2.0	0
213	Genetic Variations and Association. International Review of Neurobiology, 2010, 94, 129-151.	2.0	0
214	Defining an immune signature predictive of glioma progression. Journal of Neuroimmunology, 2014, 275, 35.	2.3	0
215	P4-074: ITALIAN NETWORK FOR AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE AND FRONTOTEMPORAL LOBAR DEGENERATION (ITALIANDIAFN). , 2014, 10, P810-P810.		О
216	Copper Subtype of Alzheimer Disease: A Genetic Study of ATP7B Frequency. American Journal of Clinical Pathology, 2015, 144, A242-A242.	0.7	0

#	Article	lF	CITATIONS
217	F49GENETIC DETERMINANTS OF CIRCULATING VEGF LEVELS IN MAJOR DEPRESSIVE DISORDER. European Neuropsychopharmacology, 2019, 29, S1135-S1136.	0.7	o
218	P.264 Association of single nucleotide polymorphisms in the $3\hat{a} \in \mathbb{M}$ untranslated region of SLC1A2 with major depressive disorder and relative endophenotypes. European Neuropsychopharmacology, 2020, 40, S150-S151.	0.7	0